IL242355B - Cannabidiol for the prevention and treatment of graft-versus-host disease - Google Patents

Cannabidiol for the prevention and treatment of graft-versus-host disease

Info

Publication number
IL242355B
IL242355B IL242355A IL24235515A IL242355B IL 242355 B IL242355 B IL 242355B IL 242355 A IL242355 A IL 242355A IL 24235515 A IL24235515 A IL 24235515A IL 242355 B IL242355 B IL 242355B
Authority
IL
Israel
Prior art keywords
cannabidiol
graft
versus
prevention
treatment
Prior art date
Application number
IL242355A
Other languages
English (en)
Hebrew (he)
Inventor
Yeshurun Moshe
Original Assignee
Mor Research Applic Ltd
Yeshurun Moshe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd, Yeshurun Moshe filed Critical Mor Research Applic Ltd
Publication of IL242355B publication Critical patent/IL242355B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL242355A 2013-05-02 2015-10-29 Cannabidiol for the prevention and treatment of graft-versus-host disease IL242355B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818525P 2013-05-02 2013-05-02
PCT/IL2014/050385 WO2014178048A1 (en) 2013-05-02 2014-04-29 Cannabidiol for the prevention and treatment of graft-versus-host disease

Publications (1)

Publication Number Publication Date
IL242355B true IL242355B (en) 2020-11-30

Family

ID=51843241

Family Applications (1)

Application Number Title Priority Date Filing Date
IL242355A IL242355B (en) 2013-05-02 2015-10-29 Cannabidiol for the prevention and treatment of graft-versus-host disease

Country Status (5)

Country Link
US (2) US9956182B2 (und)
EP (1) EP2991733B1 (und)
ES (1) ES2788744T3 (und)
IL (1) IL242355B (und)
WO (1) WO2014178048A1 (und)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934512B1 (en) 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2017218846A1 (en) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Methods and compositions for potentiating stem cell therapies
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
US10864189B2 (en) * 2018-06-29 2020-12-15 Jenna Borok Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care
CN114732807A (zh) * 2022-03-27 2022-07-12 苏州大学 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
WO2008107879A1 (en) 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US9855225B2 (en) 2011-08-18 2018-01-02 Temple University Office Of Technology Transfer Cannabinoid receptor treatments

Also Published As

Publication number Publication date
US10660865B2 (en) 2020-05-26
WO2014178048A1 (en) 2014-11-06
EP2991733A1 (en) 2016-03-09
ES2788744T3 (es) 2020-10-22
US20160101063A1 (en) 2016-04-14
EP2991733A4 (en) 2017-01-11
EP2991733B1 (en) 2020-02-19
US9956182B2 (en) 2018-05-01
US20180185300A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
IL243976B (en) kdm1a inhibitors for disease treatment
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
EP2968318A4 (en) ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1217896A1 (zh) 用於治療廣泛性發展障礙的複合物及方法
HK1219653A1 (zh) 治療線粒體疾病的方法
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
IL246286B (en) A medical preparation for the prevention and treatment of advanced myopia.
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
GB201321628D0 (en) Treatment of disease
HUP1300454A2 (hu) Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására
GB201306413D0 (en) The local treatment of ophthalmic diseases
GB201320014D0 (en) Treatment of cardiovascular disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed